Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | MAPK7 | Q13164 | 7/20 | 0.39 |
| ▸ | WHR1 | P49842 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | FLT4 | P35916 | 2/20 | 0.36 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4969262 | 0.77 | IRAK4 (0.53) | WHR1EHMT2KDRMAPK1EGFR | |
| Trifluoroacetic Acid SCHEMBL4969508 | 0.74 | EGFR (0.49) | EHMT2KDRMAPK1EGFRFGFR1 | |
| Trifluoroacetic Acid SCHEMBL4965758 | 0.74 | IRAK4 (0.57) | WHR1EHMT2KDRMAPK1EGFR | |
| Trifluoroacetic Acid SCHEMBL30264700 | 0.72 | KIT (0.46) | PDE10AMAPK7KDREGFRFGFR1 | |
| Trifluoroacetic Acid SCHEMBL29589036 | 0.71 | ACHE (0.52) | PDE10AMAPK7WHR1ENPP1MAPK1 | |
| SCHEMBL4969267 | 0.69 | MAPK7 (0.42) | PDE10AMAPK7EHMT2KDRMAPK1 | |
| Trifluoroacetic Acid SCHEMBL5528683 | 0.69 | ENPP1 (0.63) | PDE10AMAPK7WHR1ENPP1MAPK1 | |
| Trifluoroacetic Acid SCHEMBL30264814 | 0.69 | PDE10A (0.64) | PDE10AMAPK7EGFRBRAF | |
| Trifluoroacetic Acid SCHEMBL6902285 | 0.68 | KDR (0.65) | KDREGFRFGFR1FLT1FLT4 | |
| Trifluoroacetic Acid SCHEMBL5525772 | 0.67 | ENPP1 (0.58) | PDE10AENPP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899319-A2 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893206-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135649-A2 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135636-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, CDC42BPG, PRKCQ | PDE10A 4119/4885MAPK7 1294/4885WHR1 2769/4885 |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | PDE10A 2325/4885MAPK7 766/4885WHR1 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.